Baseline peripheral blood mononuclear cell (PBMC) transcriptomics before ustekinumab treatment is linked with Crohn Disease clinical response at 1 year.

No substantial differences were found in PBMC transcriptomics between responders and non-responders. However, among the non-responders, we noted an increased inflammatory response enriched for pathways linked with cytokine activity and chemokine receptor binding, and innate myeloid signature. A larger cohort is required to validate and further explore these findings.